Matching between Donors and Ulcerative Colitis Patients Is Important for Long-Term Maintenance after Fecal Microbiota Transplantation

We previously demonstrated that fresh fecal microbiota transplantation (FMT) following triple antibiotic therapy (amoxicillin, fosfomycin, metronidazole (AFM); A-FMT) resulted in effective colonization of Bacteroidetes species, leading to short-term clinical response in ulcerative colitis (UC). Its long-term efficacy and criteria for donor selection are unknown. Here, we analyzed the long-term efficacy of A-FMT compared to AFM monotherapy (mono-AFM). AFM was administered to patients with mild to severe UC for 2 weeks until 2 days before fresh FMT. Clinical response and efficacy maintenance were defined by the decrease and no exacerbation in clinical activity index. The population for intention-to-treat analysis comprised 92 patients (A-FMT, n = 55; mono-AFM, n = 37). Clinical response was observed at 4 weeks post-treatment (A-FMT, 56.3%; mono-AFM, 48.6%). Maintenance rate of responders at 24 months post-treatment was significantly higher with A-FMT than mono-AFM (p = 0.034). Significant differences in maintenance rate according to the age difference between donors and patients were observed. Additionally, sibling FMT had a significantly higher maintenance rate than parent–child FMT. Microbial analysis of patients who achieved long-term maintenance showed that some exhibited similarity to their donors, particularly Bacteroidetes species. Thus, A-FMT exhibited long-term efficacy. Therefore, matching between donors and UC patients may be helpful in effectively planning the FMT regimen.

[1]  Yan Zhou,et al.  Fecal microbiota transplantation for ulcerative colitis: a prospective clinical study , 2019, BMC Gastroenterology.

[2]  Bota Cui,et al.  Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis , 2019, Drug Safety.

[3]  L. Nezi,et al.  Fecal Microbiota Transplantation Controls Murine Chronic Intestinal Inflammation by Modulating Immune Cell Functions and Gut Microbiota Composition , 2019, Cells.

[4]  J. Caporaso,et al.  Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota , 2019, Scientific Reports.

[5]  J. Clemente,et al.  Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. , 2019, Gastroenterology.

[6]  S. Wesselingh,et al.  Bacterial viability in faecal transplants: Which bacteria survive? , 2019, EBioMedicine.

[7]  T. Vatanen,et al.  The Super-Donor Phenomenon in Fecal Microbiota Transplantation , 2019, Front. Cell. Infect. Microbiol..

[8]  J. Andrews,et al.  Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial , 2019, JAMA.

[9]  Paul Theodor Pyl,et al.  Recovery of gut microbiota of healthy adults following antibiotic exposure , 2018, Nature Microbiology.

[10]  R. Gibbs,et al.  Temporal development of the gut microbiome in early childhood from the TEDDY study , 2018, Nature.

[11]  Itai Sharon,et al.  Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT , 2018, Cell.

[12]  Sumio Watanabe,et al.  The Microbial Composition of Bacteroidetes Species in Ulcerative Colitis Is Effectively Improved by Combination Therapy With Fecal Microbiota Transplantation and Antibiotics. , 2018, Inflammatory bowel diseases.

[13]  L. Hansen,et al.  Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study , 2018, Gut.

[14]  C. Huttenhower,et al.  Dynamics of metatranscription in the inflammatory bowel disease gut microbiome , 2018, Nature Microbiology.

[15]  S. Taylor-Robinson,et al.  Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial , 2017, Hepatology.

[16]  W. D. de Vos,et al.  The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota , 2017, Microbiology and Molecular Biology Reviews.

[17]  R. Friedland,et al.  Microbiota and Aging. A Review and Commentary. , 2017, Archives of medical research.

[18]  W. Petritsch,et al.  The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis , 2017, Alimentary pharmacology & therapeutics.

[19]  R. Hagerman,et al.  The Gut Microbiota and Autism Spectrum Disorders , 2017, Front. Cell. Neurosci..

[20]  K. Kurokawa,et al.  Intestinal IgA as a modulator of the gut microbiota , 2017, Gut microbes.

[21]  M. Kamm,et al.  Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial , 2017, The Lancet.

[22]  F. Shanahan,et al.  The Gut Microbiota in Inflammatory Bowel Disease. , 2017, Gastroenterology clinics of North America.

[23]  Jing-Yuan Fang,et al.  Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy , 2017, Gut.

[24]  Linfeng Yang,et al.  Fecal microbiota transplantation in patients with slow-transit constipation: A randomized, clinical trial , 2017, PloS one.

[25]  K. Whelan,et al.  The gut microbiota of siblings offers insights into microbial pathogenesis of inflammatory bowel disease , 2017, Gut microbes.

[26]  M. Osman,et al.  Donor Efficacy in Fecal Microbiota Transplantation for Recurrent Clostridium difficile: Evidence From a 1,999-Patient Cohort , 2016 .

[27]  S. Dutta,et al.  Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in the Elderly: Long-Term Outcomes and Microbiota Changes , 2016, Digestive Diseases and Sciences.

[28]  J. Raes,et al.  Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.

[29]  E. Zoetendal,et al.  Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. , 2015, Gastroenterology.

[30]  M. Surette,et al.  Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. , 2015, Gastroenterology.

[31]  E. Zoetendal,et al.  Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. , 2015, World journal of gastroenterology.

[32]  K. Whelan,et al.  Siblings of patients with Crohn’s disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities , 2015, Gut.

[33]  Jenny Sauk,et al.  Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  C. Surawicz,et al.  Fecal microbiota transplantation and donor standardization. , 2013, Trends in microbiology.

[35]  R. Hunt,et al.  Fecal Microbiota Transplantation for Clostridium difficile Infection: Systematic Review and Meta-Analysis , 2013, The American Journal of Gastroenterology.

[36]  E. Zoetendal,et al.  Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.

[37]  E. Zoetendal,et al.  Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. , 2012, Gastroenterology.

[38]  R. Knight,et al.  Diversity, stability and resilience of the human gut microbiota , 2012, Nature.

[39]  T. Borody,et al.  Fecal microbiota transplantation and emerging applications , 2012, Nature Reviews Gastroenterology &Hepatology.

[40]  F. Bushman,et al.  Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes , 2011, Science.

[41]  T. Ohkusa,et al.  Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis , 2008, Journal of gastroenterology and hepatology.

[42]  T. Chiba,et al.  Usefulness of quantitative real‐time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies , 2007, Inflammatory bowel diseases.

[43]  Daniel B. DiGiulio,et al.  Development of the Human Infant Intestinal Microbiota , 2007, PLoS biology.

[44]  J. Braun,et al.  Body traffic: ecology, genetics, and immunity in inflammatory bowel disease. , 2007, Annual review of pathology.

[45]  J. Palmer,et al.  Investigating Deep Phylogenetic Relationships among Cyanobacteria and Plastids by Small Subunit rRNA Sequence Analysis 1 , 1999, The Journal of eukaryotic microbiology.

[46]  S. Kimoto SOME QUANTITATIVE ANALYSIS ON THE CHRY-SOMELID FAUNA OF THE RYUKYU ARCHIPELAGO , 1967 .

[47]  S. Kimoto,et al.  SOME QUANTITATIVE ANALYSIS SOMELID FAUNA OF THE RYUKYU ON THE CHRY-ARCHIPELAGO , 1967, ESAKIA.

[48]  H. S. Horn,et al.  Measurement of "Overlap" in Comparative Ecological Studies , 1966, The American Naturalist.

[49]  森下 Measuring of interspecific association and similarity between communities. , 1961 .

[50]  D. Ishikawa,et al.  P074 MICROBIAL COMPOSITION IS EFFECTIVELY IMPROVED BY COMBINATION THERAPY WITH FECAL MICROBIAL TRANSPLANTATION AND MULTIPLE ANTIBIOTICS FOR ULCERATIVE COLITIS , 2018 .

[51]  Sumio Watanabe,et al.  Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis , 2017, Inflammatory bowel diseases.

[52]  K. Zimmermann,et al.  A vegan or vegetarian diet substantially alters the human colonic faecal microbiota , 2012, European Journal of Clinical Nutrition.

[53]  C. Reiff,et al.  Inflammatory bowel disease, gut bacteria and probiotic therapy. , 2010, International journal of medical microbiology : IJMM.